A5063989546- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Lung Cancer Treatments and Mutations
- Click Chemistry and Applications
- BRCA gene mutations in cancer
- Crystallization and Solubility Studies
- X-ray Diffraction in Crystallography
- Radical Photochemical Reactions
- Monoclonal and Polyclonal Antibodies Research
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- Chemical Synthesis and Analysis
- Catalytic C–H Functionalization Methods
- Esophageal Cancer Research and Treatment
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
- Synthesis and characterization of novel inorganic/organometallic compounds
- Ovarian cancer diagnosis and treatment
- Genetic factors in colorectal cancer
Korea Advanced Institute of Science and Technology
2021-2025
Institute for Basic Science
2021-2025
Samsung Medical Center
2012-2024
Sungkyunkwan University
2012-2024
Daejeon University
2021
Government of the Republic of Korea
2021
Catalytic Materials (United States)
2021
Hôpital Lyon Sud
2019
Institut Bergonié
2019
Seoul National University Hospital
2019
Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with trastuzumab deruxtecan (T-DXd) in patients human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated emtansine (T-DM1). We report updated cumulative survival outcomes a median 26.5 months (data cut-off 26 March 2021).
•43/261 patients randomized to T-DXd and 39/263 T-DM1 had clinically inactive BMs at baseline.•For with BMs, median (95%CI) PFS was 15.0 (12.5-22.2) months for vs 3.0 (95% CI, 2.8-5.8) T-DM1.•For confirmed systemic ORR 67.4% versus 20.5% T-DM1.•Intracranial 65.7% 34.3% T-DM1.•Patients HER2+ mBC without achieved greater benefit from treatment T-DM1. BackgroundDESTINY-Breast03 is a randomized, multicenter, open-label, phase III study of trastuzumab deruxtecan (T-DXd) emtansine (T-DM1) in human...
1,4-Azaborine-based arenes are promising electroluminescent emitters with thermally activated delayed fluorescence (TADF), offering narrow emission spectra and high quantum yields due to a multi-resonance (MR) effect. However, their practical application is constrained by limited operational stability. This study investigates the degradation mechanism of MR-TADF molecules. Electroluminescent devices incorporating these compounds display varied lifetimes, uncorrelated excitonic stability or...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines diagnosis, staging and treatment patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting convened by ESMO Korean (KSMO) collaboration nine other Asian national oncology societies May 2022 order to adapt 2021 take into account differences associated MBC Asia. These represent consensus opinions reached a panel experts representing oncological...
The Paternò–Büchi reaction is the [2 + 2] photocycloaddition of a carbonyl with an alkene to afford oxetane. Enantioselective catalysis this classical photoreaction, however, has proven be long-standing challenge. Many best-developed strategies for asymmetric photochemistry are not suitable address problem because interaction carbonyls Brønsted or Lewis acidic catalysts can alter electronic structure their excited state and divert reactivity toward alternate photoproducts. We show herein...
We report the density functional theory (DFT) guided discovery of ethynyl-triazolyl-phosphinates (ETPs) as a new class electrophilic warheads for cysteine selective bioconjugation. By using Cu